Hostname: page-component-76dd75c94c-x59qb Total loading time: 0 Render date: 2024-04-30T07:29:55.282Z Has data issue: false hasContentIssue false
  • English
  • Français

Human umbilical cord blood infusions in management of autism spectrum disorder: Narrative review

Published online by Cambridge University Press:  13 August 2021

M. Adnan ,
F. Motiwala ,
Z. Mansuri  and
A. Reddy
M. Adnan*
Affiliation:
Psychiatry, Mercy Hospital and Medical Center, Lincolnwood, United States of America
F. Motiwala
Affiliation:
Psychiatry, Texas Tech University Health Sciences Center at the Permian Basin, Midland, United States of America
Z. Mansuri
Affiliation:
Department Of Psychiatry, Boston Children’s Hospital/Harvard Medical School, Boston, United States of America
A. Reddy
Affiliation:
Psychiatry, Virginia Tech Carilion School of Medicine, Roanoke, United States of America
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

According to CDC’s Autism and Developmental Disabilities Monitoring Network surveillance in 2016, autism spectrum disorder (ASD) was prevalent in 1 in 54 children in 11 states of the US.

Objectives

This systematic review provides an overview of Umbilical Cord Blood Infusion (UCB) to decrease symptoms severity in children with (ASD).

Methods

Systematic literature search was conducted using “Autism” OR “Autism spectrum disorder” AND “Autologous Umbilical Cord Blood Infusion (AUCBI)” OR “umbilical cord blood” OR “Allogeneic Cord Blood” in PubMed, Embase, and PsycINFO. Three studies were qualified on AUCBI.

Results

We found 3 studies on UCBI The UCB Infusion phase-I/ open-label trial showed significant improvement in cognitive and behavior scales, especially in the social domain in the first six months, and was more significant in children with higher baseline nonverbal intelligence quotients. Other study/phase II trial failed to show any effects of UCBI on social communication, vocabulary, and other autism symptoms. On subgroup analysis, the improvement in Clinical Global Impression - Improvement (CGI-I) in children without intellectual disability (ID) with the allogenic (not autologous) UCBI was observed. Another randomized, blinded crossover trial failed to show any difference between improvements in CGI baseline severity scores in placebo vs. cord blood infusion groups.

Conclusions

The data provides evidence to support the efficacy and safety of autologous UCBI in symptom severity reductions and improved clinical outcomes without intellectual disability. However, the evidence is inadequate and future large scale clinical are required.

Keywords

autism spectrum disorder
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S415
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.